Dabigatran Etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic
embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant
drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and
can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity
of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low
levels of individual variation. We review the pharmacological mechanisms, pharmacokinetics and drug interactions,
as well as the application of DE for different clinical populations, and provide clinical guidelines.
Keywords: Dabigatran etexilate, Novel oral anticoagulants, pharmacokinetics,
drug interactions, specific populations.
Rights & PermissionsPrintExport